BLOGS WEBSITE
Category: Sciences
Pfizer (US): Independent Grants Program – Appropriate immunisations in adult patients with immune-mediated inflammatory conditions
Pfizer, under the independent grants for learning and change programme, invites proposals for its call on appropriate immunisations in adult patients with immune-mediated inflammatory conditions. This supports education and quality improvement programmes that focus on ensuring that adult patients with immune-mediated inflammatory conditions, specifically rheumatoid arthritis, spondyloarthritis and inflammatory bowel disease, are receiving appropriate vaccinations, […]
Comments Off on Pfizer (US): Independent Grants Program – Appropriate immunisations in adult patients with immune-mediated inflammatory conditions
US National Institutes of Health: Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 – Clinical Trial Not Allowed)
Activity Code: R61/R33 Exploratory/Developmental Phased Award Funding Opportunity Announcement (FOA) Number: RFA-HD-19-015 The purpose of this funding opportunity announcement is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilisation. This opportunity aims to position innovative and validated methods for future […]
Comments Off on US National Institutes of Health: Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 – Clinical Trial Not Allowed)
US National Institutes of Health: The Role of Epitranscriptomics in Development and Disease (R21 – Clinical Trial Not Allowed)
This opportunity uses the R01 Research Project Grant funding mechanism. Funding Opportunity Announcement (FOA) Number: PAR-18-831 The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its role of epitranscriptomics in development and disease (R21 clinical trial not allowed) funding opportunity. This supports research into the role of RNA chemical modifications in […]
Comments Off on US National Institutes of Health: The Role of Epitranscriptomics in Development and Disease (R21 – Clinical Trial Not Allowed)
US National Institutes of Health: The Role of Epitranscriptomics in Development and Disease (R01 – Clinical Trial Not Allowed)
This opportunity uses the R01 Research Project Grant funding mechanism. Funding Opportunity Announcement (FOA) Number: PAR-18-830 The Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute and the National Eye Institute invite applications for their role of epitranscriptomics in development and disease (R01 clinical trial not allowed) funding opportunity. This supports […]
Comments Off on US National Institutes of Health: The Role of Epitranscriptomics in Development and Disease (R01 – Clinical Trial Not Allowed)
US NIH National Institute on Aging: Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R21 Clinical Trial Not Allowed)
This opportunity uses the R21 Exploratory/Developmental Research Grants funding mechanism. Funding Opportunity Announcement (FOA) Number: PA-18-824 This award supports analyses that will lead to a more detailed understanding of the effects of caloric restriction on risk factors for chronic diseases and the cellular and molecular mechanisms mediating the effects of sustained caloric restriction in humans. Companion Schemes PA-18-823, […]
Comments Off on US NIH National Institute on Aging: Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R21 Clinical Trial Not Allowed)
US NIH National Institute on Aging: Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R01 Clinical Trial Not Allowed)
This opportunity uses the R01 Research Project Grant funding mechanism. Funding Opportunity Announcement (FOA) Number: PA-18-823 Applications are invited for research projects (R01) involving secondary analyses of data and/or stored biospecimens from the CALERIE (Comprehensive Assessment of Long- term Effects of Reducing Intake of Energy) trial. The goal of this funding opportunity announcement (FOA) is to encourage […]
Comments Off on US NIH National Institute on Aging: Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R01 Clinical Trial Not Allowed)
US NIH National Institute on Aging: Major Opportunities for Research in Epidemiology of Alzheimer’s Disease and Cognitive Resilience (R01)
This opportunity uses the R01 Research Project Grant funding mechanism. Funding Opportunity Announcement (FOA) Number: PAR-15-356 This opportunity encourages investigator-initiated applications addressing the epidemiology of Alzheimer’s disease (AD) as well as protective factors for cognitive health and resilience. All projects in cognitive epidemiology and genetics/genomics relevant to AD are welcome. Funding & Duration Application budgets are not […]
Comments Off on US NIH National Institute on Aging: Major Opportunities for Research in Epidemiology of Alzheimer’s Disease and Cognitive Resilience (R01)
Department of Defence Next Generation Technologies Fund: Small Business Innovation Research for Defence – Call for Applications
Small Business Innovation Research for Defence (SBIRD) is a program encouraging Australian Small-to-Medium Enterprises (SMEs) (including University startups) to undertake research projects under the Next Generation Technologies Fund (Next Gen Tech Fund) in the following topic. The Australian Defence Force uses remotely piloted fixed wing aircraft for some tactical surveillance operations. When deployed over a […]
Comments Off on Department of Defence Next Generation Technologies Fund: Small Business Innovation Research for Defence – Call for Applications
US National Institutes of Health: Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional)
This opportunity uses the U01 Research Project – Cooperative Agreements funding mechanism. The goal of this scheme is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer’s disease (AD), slow its progression, or treat its cognitive and behavioural symptoms. Funding & Duration Application budgets […]
Comments Off on US National Institutes of Health: Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional)
US National Institutes of Health: Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional) – AIDS Related
This opportunity uses the U01 Research Project – Cooperative Agreements funding mechanism. The National Institute on Aging invites applications for its Alzheimer’s drug development programme (U01 clinical trial optional): AIDS-related. This supports preclinical and early stage clinical development of small-molecule and biologic therapeutic agents that prevent Alzheimer’s disease, slow its progression or treat its cognitive and behavioural symptoms. […]
Comments Off on US National Institutes of Health: Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional) – AIDS Related